TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and regulatory pathway for ...
The first stage of the Phase IIa study with YELIVA ® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous ...
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA ® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection in 55 clinical sites across the U.S. ...
Key Highlights: Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase III study with RHB-104 for Crohn’s disease - the study successfully met both its primary endpoint ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Once granted, the new formulation patent is expected to be valid until at least 2033 RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals RedHill and Salix recently amended their license agreement to include certain development activities, timelines ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Once granted, the new patent, which covers both RHB-104 and RHB-204, is expected to be valid until at least 2029 RedHill recently announced positive top-line results from the randomized, double-blind, placebo-controlled MAP US Phase III study with orally-administered RHB-104 in Crohn’s disease ...
Menu